Summary of adverse events (all grades) and treatment discontinuation in 18 patients
| . | No. (%) . |
|---|---|
| Adverse events | |
| Neuropathic pain | 1 (6) |
| Peripheral neuropathy | 2 (11) |
| Neutropenia | 1 (6) |
| Headache | 1 (6) |
| Hypertension | 1 (6) |
| Infections | 2 (11) |
| Thrombocytopenia | 7 (39) |
| Platelet count 50 × 109/L to less than 150 × 109/L | 5 (28) |
| Platelet count 25 × 109/L to less than 50 × 109/L | 2 (11) |
| Serious adverse events | |
| Death due to progressive disease | 1 (6) |
| Adverse events leading to discontinuation | |
| Progressive disease | 6 (33) |
| Neuropathic pain | 1 (6) |
| Peripheral neuropathy | 1 (6) |
| . | No. (%) . |
|---|---|
| Adverse events | |
| Neuropathic pain | 1 (6) |
| Peripheral neuropathy | 2 (11) |
| Neutropenia | 1 (6) |
| Headache | 1 (6) |
| Hypertension | 1 (6) |
| Infections | 2 (11) |
| Thrombocytopenia | 7 (39) |
| Platelet count 50 × 109/L to less than 150 × 109/L | 5 (28) |
| Platelet count 25 × 109/L to less than 50 × 109/L | 2 (11) |
| Serious adverse events | |
| Death due to progressive disease | 1 (6) |
| Adverse events leading to discontinuation | |
| Progressive disease | 6 (33) |
| Neuropathic pain | 1 (6) |
| Peripheral neuropathy | 1 (6) |